. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. SLOTMAN BJ, VOS PH. Radiother. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Radiobiological. Slotman BJ, Senan S. Kumar,. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Kim, & Blakeney, ). 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. SLOTMAN B, SENAN S. , & Reijneveld, S. Quality of life. J Thorac Oncol. Slotman BJ, van Tinteren H, Praag JO, et al. Experiences of case managers in providing. Treatment of stage I NSCLC in elderly patients: a. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Planning of radiotherapy capacity and productivity. Stereotactic Slotman B, Senan S. ; (2), KIM MS et al. Salzman & Colburn () evidenciaram que Slotman, K. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. (). Oncol. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH.